Deposit of explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
The last three paragraphs of the Biotechnology Patent Guidelines (March 2013) cover what the specification of a biotechnology invention must disclose, how claims to many sequences are tested for unity, how biological material is deposited and what the Office expects on the source of biological material and the approval of the National Biodiversity Authority.
The specification must let a skilled person reproduce everything claimed without undue experimentation (para 19). Laundry-list claims that name many unrelated diseases for a gene, and reach-through claims to compounds not yet found, are treated as unsupported or insufficient. Sequence claims can lack unity a priori or a posteriori (19.1). Biological material that cannot be described and is not available to the public must be deposited with an International Depository Authority (para 20). Source and geographical origin must be disclosed, and the Guidelines record that no patent based on Indian biological resources is to be granted without NBA approval (para 21). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from March 2013. It describes the Biological Diversity Act, 2002 as it then stood; the Act as amended in 2023 should be checked for what applies now. The statutory source is section 10; see our post on section 10, claims, abstract and biological material. For help with a biotechnology specification, see patent drafting and filing.
Sufficiency, clarity and support (paragraph 19)
The Guidelines recall section 10(4) (full and particular description, the method of performing the invention that the applicant considers most suitable, claims) and section 10(5) (claims clear, succinct and fairly based). They say disclosure and claims have different purposes but support each other: disclosure is the essential part of the bargain with the public, and the claims tell the public the forbidden area.
TaxClue's table of the main rules:
| Topic | What the Guidelines say | What it means for the draft |
|---|---|---|
| Whole scope | At least one method must be described so that the whole subject matter claimed can be carried out without undue experimentation or inventive ingenuity; if the skilled person has to find something new to reproduce the invention, the disclosure is insufficient | Support every claim with a working method |
| Broad, speculative claims | Treated as not supported by the description | Limit to what is shown |
| Laundry list | Where the specification lists many unrelated diseases as potential targets of a gene or protein, the claims are treated as having a laundry list; even if one disease association is established, that does not support use in many others; without evidence for each listed disease, the specification is insufficient | Claim only the uses you have evidence for |
| Reach-through | Claims that reach to things not identified at filing but findable by the applicant's process are not patentable for insufficiency | Claim the products you have identified |
| Embodiment | Each claim needs an embodiment, enabling the industry to work it without further invention, and the description must be fair and not unnecessarily hard to follow | Write for the reader |
| Date | The relevant date is the date of the complete specification; later developments in the art cannot cure an insufficient specification | Do not plan to fix it later |
| Variants | Analogues or variants by addition, substitution or deletion can be almost infinite; claims should be limited to variants disclosed that share a common specific activity which is not predictable | Disclose the variants and their activity |
| Hybridising sequences | A claim to sequences defined by hybridisation to a probe and an activity is unsupported if the hybridisation conditions are not disclosed and the skilled person must experiment unduly | State the conditions |
| Antibodies | Claims to antibodies with potential therapeutic or diagnostic use are unsupported if a role for the target protein in a specific disease has not been identified and proved by data | Show the target's role with data |
The Guidelines cite Raj Prakash v Mangat Ram Chowdhry, following Farbwerke Hoechst v Unichem Laboratories, as cited, for the embodiment rule.
The Guidelines' example. A claim to screening a polypeptide against a compound to see whether it affects activity and then formulating any active compound into a pharmaceutical composition. The Office says screening of existing material does not give a product, and the claim reaches through to compounds not yet identified. Without a known relationship, the skilled person would not know how to make and use the compounds, and screening undefined compounds is undue burden. There is also a lack of support where the function of the identified compounds is not specified.
Unity of invention for sequences (paragraph 19.1)
The Guidelines note that gene technology applications often claim many polynucleotide and polypeptide sequences, which raises problems at publication, search and examination, and that it is not always clear whether the sequences form a single invention or a group linked by a single inventive concept. Lack of unity can be:
- A priori: before considering prior art, if the claim groups share no same or corresponding technical feature;
- A posteriori: after the search, if the shared feature makes no contribution over the prior art.
The examples in the Guidelines:
| Example | Scenario | Finding |
|---|---|---|
| A priori | Three claims to DNA constructs for improved expression, each built around a different promoter sequence | The three promoter sequences share no common structural feature, so no special technical feature unifies them: three separate inventions |
| A posteriori | Two compositions combining a known group of heterocycles with two different proteins to identify a gene for a cancer | The heterocycle group is already known and so is not a special technical feature; the claims lack unity a posteriori |
The unity of invention in pharmaceutical claims is explained in our article on paragraph 12 of the Pharmaceutical Guidelines, and the Manual's version in our article on sufficiency and unity.
Deposit of biological material (paragraph 20)
If the invention involves a biological material that cannot be described sufficiently and is not available to the public, the application is completed by depositing the material with an International Depository Authority under the Budapest Treaty. According to the Guidelines:
- the deposit is to be made not later than the date of filing in India;
- a reference to the deposit is given in the specification within three months from the date of filing;
- the specification includes all available characteristics needed to identify the material, the name and address of the depository and the date and number of the deposit.
The reference to depositary authorities in section 10(4) is to be read with section 2(1)(aba). The three-month period agrees with rule 13(8) as described in our post on the rule on the abstract, title and deposit reference, which also records a proviso linked to a request for early publication; the rule post prevails.
Biodiversity (paragraph 21) and source of origin
The Guidelines say that the Biological Diversity Act requires access to Indian biological resources to be subject to equitable benefit sharing through approval of the National Biodiversity Authority, and that no intellectual property rights, including patents, based on research or information on biological resources obtained from India are to be granted without that approval. They also say disclosure of the source and geographical origin of biological material used in an application is mandatory under section 10(4), that section 3(p) prohibits patenting of traditional knowledge in effect, and that the Controller General's instructions on traditional knowledge and biological material should be strictly followed.
This is the 2013 statement. The Act as amended in 2023 should be checked, and so should the current Form 1; see our post on the forms as substituted in 2024 and our article on the Traditional Knowledge Guidelines, Form 1 and NBA permission.
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Can the whole claimed scope be reproduced? | A working method and examples across the claimed variants |
| Is each listed use supported? | Evidence for each disease or use claimed |
| Do the claimed sequences form one invention? | A shared structural or functional feature that is new over the prior art |
| Is biological material deposited, and is the reference made on time? | Deposit with an International Depository Authority, with details in the specification |
| Is the source and geographical origin stated? | The source and origin in the specification and the correct form declaration |
A worked example (invented)
Sagar Marine Biotech files claims to a gene from a sea-sponge-associated bacterium, saying the protein may treat arthritis, diabetes, depression, asthma and hypertension. The examiner objects that the use list is a laundry list and that the bacterial strain has not been deposited. Sagar restricts the claims to the one use for which its specification gives cell assay data, deposits the strain with an International Depository Authority and files the reference within the period in rule 13(8), and states the sponge's collection site in the specification. The reply shows evidence for each use claimed and the deposit particulars.
Common lapses
- Listing many diseases for a gene on the strength of one assay.
- Claiming screening methods that end in "any compound found".
- Leaving out hybridisation conditions in a hybridising-sequence claim.
- Making the deposit after the filing date, or giving no reference to it in the specification.
- Omitting the source and origin when biological material is used.
Need help with a biotechnology specification or deposit?
Deposit timing, source disclosure and claim scope are easy to get wrong and hard to fix after filing. Our team can check your draft against these paragraphs before it is filed. See patent drafting and filing, and read the related Guidelines on the kinds of biotechnology claims.
Key takeaways
- Every claim needs an embodiment, and the whole scope must be reproducible without undue experimentation.
- Laundry-list and reach-through claims are treated as insufficient.
- Sequence claims can lack unity a priori or a posteriori.
- Deposit with an International Depository Authority is needed for material that cannot be described and is not publicly available.
- The 2013 biodiversity statement predates the 2023 amendment of the Act.
Read next
- Biotechnology Patent Guidelines 2013, paragraphs 1 to 5: scope and kinds of claims
- TK and Biological Material Guidelines 2012: screening, Form 1 and NBA permission
- Manual Chapter 9: sufficiency of disclosure and unity of invention
- Rule 13 of the Patents Rules, 2003: abstract, title and deposit of biological material
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.